Evidence map›Paper›PMID 28730158›Full record

ArticleOpen forum infectious diseases2017

A Rapid Epidemiological Tool to Measure the Burden of Norovirus Infection and Disease in Resource-Limited Settings.

Daniel Olson, Molly M Lamb, Maria Renee Lopez, M Alejandra Paniagua-Avila, Alma Zacarias, Gabriela Samayoa-Reyes, Celia Cordon-Rosales, Edwin J Asturias

Abstract read
In one paragraph

Article in Open forum infectious diseases, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Risk-based Vaccines and the Need for Risk-based Subnational Vaccination Strategies for Introduction.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2020
    Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Daniel OlsonDepartments ofPediatrics and.
Molly M LambCenter for Global Health and.
Maria Renee LopezCentro de Estudios en Salud, Universidad del Valle de Guatemala, Guatemala City, Guatemala.
M Alejandra Paniagua-AvilaCenter for Human Development, Fundacion para la Salud Integral de los Guatemaltecos,Coatepeque, Quetzaltenango, Guatemala; and.
Alma ZacariasCenter for Human Development, Fundacion para la Salud Integral de los Guatemaltecos,Coatepeque, Quetzaltenango, Guatemala; and.
Gabriela Samayoa-ReyesCenter for Global Health and.
Celia Cordon-RosalesCentro de Estudios en Salud, Universidad del Valle de Guatemala, Guatemala City, Guatemala.
Edwin J AsturiasDepartments ofPediatrics and.

Funding

Colorado Clinical and Translational Sciences InstituteUL1TR001082 · NCATS · UNIVERSITY OF COLORADO DENVER · PI SOKOL, RONALD J. · 2013 to 2017
$48.0M
NCATS NIH HHS UL1 TR001082
6 · The paper itself

Abstract

backgroundRapid, cost-effective tools are needed to estimate the disease burden of acute gastroenteritis (AGE) and norovirus (NoV) in resource-limited settings.

methodsHouseholds with children (6 weeks-17 years) in rural Guatemala were randomly enrolled into 2 parallel AGE surveillance systems: (1) a prospective cohort, which included an enrollment visit followed by 1 year of prospective observation using a smartphone-based weekly symptom diary; and (2) 2 sequential cross-sectional rapid active sampling (RAS) surveys. Norovirus testing was performed during enrollment (all subjects) and for prospective AGE episodes (prospective cohort only).

resultsThe prospective cohort enrolled 207 households (469 children) from April to September 2015 followed by 471 person-years of observation; RAS survey 1 enrolled 210 households (402 children) during October to November 2015, and RAS survey 2 enrolled 210 separate households (368 children) during January to February 2016. The prospective cohort detected a NoV+ AGE prevalence of 11% and a population-attributable fraction (PAF) of -1.6% at enrollment, followed by an incidence of 1.4 episodes/100 person-years. Rapid active sampling surveys 1 and 2 identified a NoV+ AGE prevalence of 14%-21% and a PAF of 3.2%-12.4%.

conclusionsRapid active sampling surveys were practical and identified more cases of NoV infection and disease compared with a parallel prospective cohort in rural Guatemala.

Indexed as

attributable fraction.Guatemalanorovirusprevalencesurveillance

Identifiers

PMID28730158
PMCPMC5510458

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.